|
|
Article: Dynavax Reports Interim TOLAMBA(TM) Ragweed Allergy Results From DARTT Trial.
- Article from:
- PR Newswire
- Article date:
- January 8, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Insufficient Ragweed Allergic Disease in Placebo and Treated Groups Prevent Measurement of Therapeutic Effect
BERKELEY, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced today that the analysis of interim one-year data from its two-year DARTT ragweed allergy trial indicated that no meaningful ragweed-specific allergic disease was observed in the study population, making it impossible to measure the therapeutic effect of TOLAMBA treatment. In all three arms of the study, including the placebo arm, minimal change from baseline was observed in the main efficacy measure of the study, the total nasal symptom score (TNSS). The ...